Suggestions
Jean-Loup Romet-Lemonne, MD
Biotech Entrepreneur
Jean-Loup Romet-Lemonne, MD is a prominent figure in the biotechnology industry, serving as the President and Co-Founder of Traverse Biotech, Inc.3 His extensive experience and expertise in the field of immunology and cancer research have positioned him as a key leader in the development of innovative cancer therapies.
Professional Background
Dr. Romet-Lemonne has a distinguished career spanning several decades in the pharmaceutical and biotechnology sectors. Prior to his role at Traverse Biotech, he held significant positions including:
- Senior Advisor at Celdara Medical
- Senior Advisor for Global Development at Institut Pasteur
- Founder and CEO of IDM Pharma, Inc., a NASDAQ-listed company that was later acquired by Takeda Oncology1
Current Role at Traverse Biotech
At Traverse Biotech, Dr. Romet-Lemonne plays a crucial role as the Co-Founder, President, and Principal Investigator.23 The company focuses on late-stage preclinical and early clinical development of immunotherapy products, with a particular emphasis on cancer treatments.
Recent Achievements
Under Dr. Romet-Lemonne's leadership, Traverse Biotech has made significant strides in cancer research:
- The company was recently awarded a Phase I SBIR grant from the National Cancer Institute to develop targeted immunotherapy for selected solid tumors.2
- They are working on a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC).2
Expertise and Contributions
Dr. Romet-Lemonne's expertise lies in:
- Immunology and cancer immunotherapy
- Drug development and clinical trials
- Biotechnology entrepreneurship
His contributions to the field are evident in his role as Program Director at the International Union of Immunological Societies (IUIS), an umbrella organization for regional and national immunology societies.6
With over 500 connections on LinkedIn, Dr. Romet-Lemonne maintains an active professional network, sharing insights and updates about advancements in biotech and immunotherapy.45
Highlights
It is a great pleasure to read this interview of Carl June delivering his thoughts about CAR-T Cell Therapy, sharing his experience as pioneer to transform his discovery into a breakthrough for leukemia therapy, witnessing the present development of CAR-T cell clinical applications and looking ahead at CAR cell technology's perspectives. Thanks Dr Carl June. #CAR-T, #immunotherapy, #Leukemia, #Carljune, #startup, #pharma, #celltherapy, #biotech
This “MUST read” STAT’s article from Ed Silverman points out the major increase of antibiotic resistance due to COVID’s pandemic. It also explain what measures are starting to be implemented by the industry, institutions and governments to act before things are getting out of control. Read it! There is clear explanation of “the PASTEUR act” and other measures. #covid #antibioticresistance #AMR #CDC #Pasteuract #government #barda #NIH #drugprices #biotech #infection #hospital #pandemic
